CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal cancer.
  
  LEARNING OBJECTIVES

  • Develop a long-term plan to guide the selection and sequencing of therapies for metastatic CRC (mCRC), considering the patient’s biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment.
  • Appreciate published research data documenting the efficacy of combined BRAF/EGFR inhibition for patients with relapsed/refractory mCRC and a BRAF V600E mutation, and optimally incorporate this therapeutic strategy into disease management.
  • Recognize available data with anti-HER2 therapy for patients with HER2-positive mCRC, and consider the current and future roles of various investigational approaches.
  • Evaluate available data with and the FDA approvals of immune checkpoint inhibitor therapies for microsatellite instability-high or mismatch repair-deficient mCRC, and optimally select patients for treatment with these approaches.
  • Apply available and emerging research in selecting and sequencing later-line therapeutic options for patients with multiregimen-relapsed mCRC.
  • Consider the potential clinical role of investigational applications for minimal residual disease using circulating tumor DNA assessment to guide adjuvant therapy decision-making.
  • Assess available trial data and ongoing clinical trials evaluating immune checkpoint inhibitor therapies as (neo)adjuvant treatment for microsatellite instability-high/mismatch repair-deficient localized CRC.
  • Recall ongoing trials evaluating novel agents and strategies for CRC, and use this information to refer appropriate patients for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty and moderator reported relevant financial relationships with ineligible entities:
  
  Tanios Bekaii-Saab, MD
  Professor, Mayo Clinic College of Medicine and Science
  Program Leader, Gastrointestinal Cancer
  Mayo Clinic Cancer Center
  Consultant, Mayo Clinic in Arizona
  Chair, ACCRU Research Consortium
  Phoenix, Arizona
  
  Consulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merck KgaA, Merus BV, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Caladrius Biosciences, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences, Foundation Medicine, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, MJH Life Sciences, Natera Inc, Swedish Orphan Biovitrum AB, Stemline Therapeutics Inc, Treos Bio; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Suzhou Kintor; Inventions/Patents: WO/2018/183488 licensed to Imugene, WO/2019/055687 licensed to Recursion; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Scientific Advisory Board: Artiva Biotherapeutics Inc, Immuneering Corporation, Imugene, Replimune, Sun Biopharma, Xilis; Nonrelevant Financial Relationship: Pancreatic Cancer Action Network.
  
  Scott Kopetz, MD, PhD
  Professor and Deputy Chair
  Department of Gastrointestinal Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AbbVie Inc, Amal Therapeutics SA, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicara Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Carina Biotech, Daiichi Sankyo Inc, EMD Serono Inc, Endeavor Biomedicines, Flame Biosciences, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, HalioDx, Holy Stone Healthcare Co Ltd, Inivata, Ipsen Biopharmaceuticals Inc, Iylon Precision Oncology, Jacobio Pharmaceuticals Group Co Ltd, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Lutris Pharma, Merck, Mirati Therapeutics Inc, Natera Inc, Novartis, Numab, Pfizer Inc, Pierre Fabre, Redx Pharma Plc, Repare Therapeutics, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Xilis.
  
  John Strickler, MD
  Associate Professor
  Duke University
  Durham, North Carolina
  
  Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, GlaxoSmithKline, Lilly, Natera Inc, Pfizer Inc, Pionyr Immunotherapeutics, Seagen Inc, Silverback Therapeutics, Takeda Pharmaceuticals USA Inc, Viatris; Consulting Agreement: Zentalis Pharmaceuticals; Contracted Research: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, Gossamer Bio, Leap Therapeutics Inc, Lilly, Nektar, Sanofi, Seagen Inc, Silverback Therapeutics; Data and Safety Monitoring Board/Committee: AbbVie Inc, BeiGene Ltd, Pionyr Immunotherapeutics; Nonrelevant Financial Relationship: AStar D3.
  
  Eric Van Cutsem, MD, PhD
  Professor of Medicine
  Digestive Oncology
  University Hospitals Leuven
  Leuven, Belgium
  
  Advisory Committee: AbbVie Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, GlaxoSmithKline, Halozyme Inc, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Mirati Therapeutics Inc, Novartis, Pierre Fabre, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation, TRIGR (trial), Zymeworks Inc; Research Grants to Institution: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Roche Laboratories Inc, Servier Pharmaceuticals LLC.
  
  MODERATOR
  
  Kristen K Ciombor, MD, MSCI
  Associate Professor of Medicine
  Division of Hematology/Oncology
  Vanderbilt-Ingram Cancer Center
  Nashville, Tennessee
  
  Advisory Committee and Consulting Agreements: Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis Inc, Pfizer Inc, Replimune, Seagen Inc; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc, Seagen Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Exelixis Inc, Lilly, Natera Inc, and Seagen Inc.
  
  Release date: February 2023
  Expiration date: February 2024